Background: After an initial episode of atrial fibrillation (AF), patients may develop long-standing persistent or permanent AF. Objective: We evaluated whether use of statins, angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), or β-blockers is associated with lower risk of long-standing persistent AF after an initial AF episode. Methods: We conducted a population-based inception cohort study of participants enrolled in Group Health, aged 30 to 84 years, with newly diagnosed AF in [2001][2002][2003][2004]. We included only participants whose initial AF episode terminated within 6 months of onset. We ascertained the primary outcome of long-standing persistent AF from medical records, electrocardiograms, and administrative data. We determined time-varying medication use from Group Health pharmacy data. Results: Among 1317 participants with incident AF, 304 developed long-standing persistent AF. Our study suggests that current statin use versus never use may be associated with lower risk for long-standing persistent AF. However, the association was not statistically significant when adjusted for age, sex, cardiovascular risk factors, and current use of antiarrhythmic medication (hazard ratio [HR] = 0.77; 95% CI = 0.57, 1.03). In lagged analyses intended to reduce healthy user bias, current statin use 1 year prior versus never use 1 year prior was not associated with risk for long-standing persistent AF (HR = 0.91; 95% CI = 0.67, 1.24). ACE inhibitor, ARB, and β-blocker use were not associated with risk for long-standing persistent AF. Conclusions: Current statin use may confer protection that wanes after discontinuing use. Alternatively, healthy user bias or chance may explain the association. The association of statin use with long-standing persistent AF warrants further investigation.
Introduction
Patients who have had a first-diagnosed episode of atrial fibrillation (AF) that terminates usually experience recurrent AF episodes, and some later progress to persistent or permanent AF. 1 Concepts of AF subtypes have evolved over time. Current guidelines define paroxysmal AF as terminating within 7 days of onset, persistent AF as being sustained longer than 7 days, long-standing persistent AF as being sustained longer than 12 months, and permanent AF as a decision to stop attempting to restore or maintain sinus rhythm. 1 Some recent studies suggest that persistent, longstanding persistent, or permanent AF are associated with worse prognoses than paroxysmal AF, including higher rates of thromboembolism, 2-5 heart failure, 4, 6, 7 myocardial infarction, 3 mortality, 5, 6 and hospitalization. 2, 3 Moreover, restoration and maintenance of sinus rhythm is more difficult to achieve in persistent AF than in paroxysmal AF. 1, 8 Patients with ongoing persistent AF report lower quality of life 9, 10 and have lower exercise capacity 10 on average compared with patients diagnosed with persistent AF who achieved and maintained sinus rhythm through treatment. Given the potential for adverse outcomes associated with persistent, long-standing persistent, or permanent AF, identifying modifiable risk factors for AF progression is important. 11 Patients with AF often receive lipid-lowering and antihypertensive medications because of comorbidities, including hyperlipidemia, hypertension, coronary heart disease, valvular heart disease, and heart failure. Use of cardiovascular medications might affect the prognosis of AF by modulating the heart's susceptibility to arrhythmia. Prior studies suggest that use of statins, [12] [13] [14] [15] angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs), [16] [17] [18] and β-blockers 19, 20 may reduce AF incidence or progression. In this study, we assessed whether use of these agents is associated with lower risk of long-standing persistent AF among study participants whose initial AF episode terminated.
Methods

Study Design, Setting, and Participants
Participants were enrollees of Group Health, an integrated health system in Washington state. They were enrolled in this observational population-based inception cohort study at the date of onset of their initial AF episode, defined as the first electrocardiogram (ECG)-confirmed occurrence of AF or atrial flutter followed by documented sinus rhythm within 6 months. We included participants with atrial flutter because it often coexists with AF in the same individual, and AF may be misdiagnosed as atrial flutter. 1 Study methods were detailed previously. 21, 22 The Group Health Human Subjects Review Committee approved the study. Waiver of consent was granted for participants with language or cognitive difficulty and for participants who had died. All other participants provided written consent or verbal consent by telephone.
Group Health enrollees were eligible for this study if they were 30 to 84 years old, experienced their initial AF episode between October 2001 and December 2004, had not received a prior AF diagnosis code during their entire Group Health enrollment (mean of 22 years), and their initial AF episode terminated either spontaneously or by pharmacological or electrical cardioversion within 6 months. We excluded participants who had perioperative AF that resolved before hospital discharge, participants who had AF as part of a hospitalized terminal illness, and participants who had a pacemaker implanted prior to their initial AF episode. We used inpatient and outpatient ICD-9 codes 427.31 (AF) and 427.32 (atrial flutter) to identify AF and confirmed eligibility by medical record review. We required that medical records showed that initial AF was confirmed by 12-lead ECG and recognized by a physician. Finally, we required participants to have had at least 4 Group Health visits before their initial AF episode to increase the likelihood that information would be available on preexisting health conditions.
During the study period there were 1953 participants with newly diagnosed AF. We excluded 391 whose initial AF episode did not terminate within 6 months, 122 who had less than 6 months of follow-up after their initial AF episode terminated, and 123 who had missing values for covariates used in multivariate models, leaving 1317 participants eligible for analyses of long-standing persistent AF.
Assessment of Medication Use and Covariates
Prescription medication use was assessed from the Group Health automated pharmacy database, which contains records of all prescriptions filled at Group Health pharmacies since 1977. Among Group Health members aged 65 years and older (not the present study participants specifically), 96% report filling all or almost all prescriptions through Group Health pharmacies. 23 Each pharmacy record includes medication type, daily dose, quantity dispensed, and intended days supply of the prescription. We used pharmacy records to create time-varying medication use variables, updated daily from before initial AF onset through the end of follow-up. For each medication, a participant's follow-up days were classified as current use when the most recent prescription filled included enough pills to last through the current date, assuming 80% adherence to prescribing instructions. Otherwise, follow-up days were classified as former use, if the participant had ever filled a prescription for the medication in the past, or never use, if the participant had never filled a prescription for the medication. This approach for creating time-varying medication use variables was applied to statins, antihypertensive medications, and antiarrhythmic medications. We identified modal daily dose of each medication from the distribution of daily dose values from all prescriptions for that medication. For periods of current use, daily dose was categorized as low (below modal dose), medium (modal dose), or high (above modal dose). 22 Baseline clinical characteristics were determined by medical record review as follows, using information recorded up to the day prior to the initial AF episode. Body mass index was calculated as Weight (kg)/Height (m 2 ) using the most recent weight prior to the initial AF episode and height measured during adulthood. Diabetes was defined as physician diagnosis plus current use of insulin or other antidiabetic agents. Systolic and diastolic blood pressures were the most recent outpatient measurements prior to the initial AF episode. Hypertension was defined as physician diagnosis plus current use of antihypertensive medication. Total cholesterol to high-density lipoprotein (HDL) cholesterol ratio was calculated as Total cholesterol (mg/dL)/HDL cholesterol (mg/dL), using the most recent measurements prior to the initial AF episode. Coronary heart disease was defined as history of hospitalization for myocardial infarction, coronary artery bypass, or angioplasty or physician diagnosis of probable or definite angina. Chronic heart failure was defined as physician diagnosis plus ongoing medical treatment with medications such as furosemide, ACE inhibitors, digitalis, vasodilators, hydralazine, nitrates, or β-blockers, as documented in the medical record. Valvular heart disease was defined as physician diagnosis of moderate to severe valvular heart disease or a prosthetic valve. History of stroke was defined as physician diagnosis of definite or probable stroke. Chronic kidney disease was defined as estimated glomerular filtration rate <60 mL/min/1.73 m 2 by the CKD-EPI equation, 24 using the most recent serum creatinine measurement prior to the initial AF episode. Participants who were missing values for these characteristics were excluded from analyses (123 participants were missing body mass index, chronic kidney disease, or total cholesterol to HDL ratio).
Ascertainment of Long-standing Persistent AF
Rhythm status during follow-up was determined from 3 data sources as follows:
1. From medical records, we obtained dates and results of ECGs, Holter monitors, rhythm strips, electrical cardioversions, other types of rhythm documentation, and results of AF ablation and maze procedures, from the initial AF episode through the date of medical record review-a mean of 2 years after the initial AF episode. 2. From the Group Health ECG database, we obtained dates and results of all ECGs done at Group Health facilities, all of which were interpreted by Group Health cardiologists for presence or absence of AF, from the initial AF episode through December 31, 2009-a mean of 7 years after the initial AF episode.
From Group Health administrative databases, we
obtained dates of ICD-9 and Current Procedural Terminology (CPT) procedure codes for electrical cardioversion (ICD-9: 99.61 and 99.62; CPT: 92960) and ablation and maze procedures (ICD-9: 37.33 and 37.34; CPT: 93651). We used these codes to augment information available from medical records, from the initial AF episode through December 31, 2009-a mean of 7 years after the initial AF episode. Specificity of each electrical cardioversion, ablation, and maze procedure code was ≥99% relative to procedures documented in medical records, suggesting that using these codes to detect the presence of AF was appropriate for follow-up beyond the time period covered by medical record review.
Using data from sources described above, we defined long-standing persistent AF as AF present after the initial AF episode terminated, on 2 separate occasions, 6 to 36 months apart, with no documented sinus rhythm in the interim. Although guidelines suggest defining longstanding persistent AF as AF present for 12 months, 1 we used 6 months as a lower bound to increase sensitivity for detecting long-standing persistent AF in participants who may have had incomplete or infrequent rhythm documentation. Recognizing that our ability to detect long-standing persistent AF in Group Health data was imperfect, in sensitivity analyses, we modified the definition of long-standing persistent AF to require AF present on 4 separate occasions 6 to 36 months apart, 2 occasions 12 to 36 months apart, or 2 occasions 6 to 18 months apart.
On recurrence of AF, we required a minimum of 6 months of follow-up to establish whether the outcome of long-standing persistent AF occurred. Therefore, participants who had less than 6 months of follow-up after the initial AF episode terminated were excluded from analyses. For the same reason, participants who had at least 6 months of follow-up who reached the end of the study without meeting the definition of long-standing persistent AF were censored 6 months prior to the end of their follow-up time. Thus, analysis of follow-up time for long-standing persistent AF ended on the first date of the qualifying long-standing persistent AF interval or 6 months prior to whichever of the following occurred first: death, an AF ablation or maze procedure, disenrollment from Group Health, or end of the study on December 31, 2009.
Statistical Analysis
We used Cox proportional hazards models with study time as the time scale to estimate cause-specific hazard ratios (HRs) and 95% CIs. 25 Time zero was date of onset of the initial AF episode. Follow-up time was left truncated, with each participant entering follow-up when his or her initial AF episode terminated. 26 Termination of AF occurred within 7 days of onset of the initial AF episode in 71% of participants but was allowed to be up to 6 months after onset. We examined associations of time-varying use of statins, ACE inhibitors or ARBs, and β-blockers with risk of long-standing persistent AF, adjusted for age, sex, and baseline clinical characteristics, including body mass index, diabetes, hypertension, coronary heart disease, valvular heart disease, heart failure, prior stroke, chronic kidney disease, and time-varying use of antiarrhythmic medication. Models for statins were also adjusted for baseline total cholesterol to HDL ratio. Models for ACE inhibitors or ARBs and for β-blockers were also adjusted for baseline systolic and diastolic blood pressure.
Our primary interest was comparing the risk for longstanding persistent AF among participants currently using a medication as of the previous day of follow-up (current use) versus participants never having used that medication as of the previous day of follow-up (never use). In our analyses, we addressed 2 potential biases that may arise in epidemiological studies of medication use: healthy user bias and confounding by indication. For analyses of statin use and ACE inhibitor or ARB use, healthy user bias may arise because participants who continue use of medications may tend to have better underlying health than participants who discontinue use of medications. To address the possibility of healthy user bias, we analyzed former use versus never use as well as current use 1 year prior to outcome occurrence and former use 1 year prior to outcome occurrence versus never use 1 year prior to outcome occurrence (1-year lagged analyses). For analyses of β-blocker use, confounding by indication may arise because β-blockers are used for heart rate control in AF, and participants receiving versus not receiving treatment for rate control might have different underlying risks of long-standing persistent AF. To address the possibility of confounding by indication, we analyzed current β-blocker use versus current nondihydropyridine calcium channel blocker (CCB) use, another rate-control treatment, rather than current β-blocker use versus never use.
Results
Baseline characteristics of the cohort of 1317 participants followed for long-standing persistent AF are shown in Table  1 . During follow-up, participants used statins for 38% of follow-up time, ACE inhibitors or ARBs for 43% of followup time, and β-blockers for 52% of follow-up time. Use of these medications during follow-up was more common among participants with baseline clinical cardiovascular disease, obesity, diabetes, hypertension, and chronic kidney disease than among participants without these characteristics. Antiarrhythmic medication use was uncommon in this cohort after the initial diagnosis of AF; during follow-up, participants used amiodarone for 5% of follow-up time and other antiarrhythmic agents for 2% of follow-up time. There were 304 cases of long-standing persistent AF and 257 deaths during a mean of 3.8 years of follow-up.
Results of adjusted models for long-standing persistent AF are shown in Table 2 . HRs were similar across age-and sex-adjusted and fully adjusted models. Current statin use versus never use was associated with a 23% lower risk of long-standing persistent AF, though the estimate did not reach statistical significance (HR = 0.77; 95% CI = 0.57, 1.03). Analyses of current daily statin dose suggested that high-dose statin use versus never use may be associated with lower risk for long-standing persistent AF (HR = 0.61; 95% CI = 0.36, 1.03). Medium dose statin use versus never use may also be associated with lower risk (HR = 0.70; 95% CI = 0.49, 1.00). Low-dose statin use versus never use was not associated with long-standing persistent AF (HR = 1.08; 95% CI = 0.70, 1.66). The trend in risk for the outcome across statin dose categories was statistically significant (for each higher-dose category: HR = 0.84; 95% CI = 0.73, 0.97). In contrast, current statin use 1 year prior versus never use 1 year prior was not associated with risk of longstanding persistent AF. Former statin use versus never use was not associated with risk of long-standing persistent AF in either nonlagged or lagged analyses. ACE inhibitor or ARB use and β-blocker use were not associated with risk of long-standing persistent AF. Modifying the definition of long-standing persistent AF resulted in lower numbers of long-standing persistent AF events. Long-standing persistent AF by these modified definitions occurred at a lower rate among current statin users compared with never users, just as in our primary analysis. However, these sensitivity analyses lacked sufficient precision and did not support a statistically significant association of current statin use with lower risk of long-standing persistent AF (Table 3 ).
Discussion
In this population-based inception cohort study of participants whose initial AF episode terminated, we observed that current statin users had a lower risk of long-standing persistent AF than participants who had never used statins. However, this association fell short of statistical significance. Use of ACE inhibitors, ARBs, or β-blockers was not associated with risk of long-standing persistent AF.
Our finding for current statin use may reflect an acute protective effect of statin use that does not persist after statin discontinuation. Alternatively, our finding may result from healthy user bias or chance. Although the risk of longstanding persistent AF was estimated as 23% lower among current statin users than among never users, the 95% CI contained the null hypothesis of a HR of 1.0, reducing our ability to rule out chance as an explanation. Healthy user bias could occur if participants who initiate or persist with statin use tend to be healthier, perhaps carrying a lower underlying risk of long-standing persistent AF, whereas those who discontinue statin use tend to be less healthy, perhaps carrying a higher underlying risk of long-standing persistent AF. Healthy user bias was illustrated in a study of statin use and incident dementia, wherein current statin use was associated with lower dementia risk, but current statin use 1 year prior was not associated with dementia risk, and former statin use 1 year prior was associated with higher dementia risk. 27 In our study, statin discontinuation was not associated with higher risk of long-standing persistent AF. Our analysis did not provide support for healthy user bias but also did not rule it out as an explanation. Points in favor of a modest protective effect of current statin use include the dose-dependent relationship we observed in this study, biological plausibility of an effect of statins on AF pathogenesis through reducing inflammation and oxidative stress, 28 and consistency with recent meta-analyses, which showed lower risk of AF recurrence among statin users. 12, 14, 15 Our study provides new information by focusing on long-standing persistent AF, which may be a more severe outcome than recurrent AF. [2] [3] [4] [5] [6] [7] [8] [9] [10] ACE inhibitor or ARB use versus diuretic use was associated with lower risk of new-onset AF among Group Health enrollees with hypertension. 22 Meta-analyses of randomized trials have shown that ACE inhibitors and ARBs reduce risk for recurrent AF. [16] [17] [18] However, the GISSI-AF trial of valsartan versus placebo showed no relationship with AF recurrence or progression after cardioversion. 29 Consistent with the GISSI-AF trial, we did not observe an association of ACE inhibitor or ARB use with long-standing persistent AF in our study. β-Blockers have been shown to reduce the incidence of new-onset AF in patients with heart failure 20 and to reduce recurrent AF after cardioversion. 19 β-Blocker use versus diuretic use was not associated with lower risk of new-onset AF among Group Health enrollees with hypertension, 22 but β-blocker use versus CCB use was associated with lower Abbreviations: ACE, angiotensin-converting enzyme; AF, atrial fibrillation; ARB, angiotensin receptor blocker; CCB, calcium channel blocker; HDL, high-density lipoprotein. a Baseline characteristics were determined by medical record review using information recorded up to the day prior to the initial AF episode; 4 participants had missing values for race, 4 for years of Group Health enrollment, and 18 for location of initial AF diagnosis. b The units mg/dL may be converted to mmol/L by multiplying by 0.0259.
risk of new-onset AF among patients in the United Kingdom General Practice Research Database. 30 β-Blockers are a common treatment for rate control in AF 1 and, therefore, would tend to be prescribed preferentially to patients thought to be most likely to experience AF recurrence or progression. Therefore, when comparing current β-blocker use with never use or nonuse, we might expect to see higher rates of long-standing persistent AF among β-blocker users, obscuring any potential inverse association. To reduce this possibility, we compared β-blockers with nondihydropyridine CCBs, which are also used for rate control. 1 Using this approach, we found no association of β-blocker use with risk of long-standing persistent AF.
Our study had strengths, including a cohort representative of routine clinical practice, broad inclusion criteria to enhance generalizability, comprehensive assessment of prescription medication use based on the Group Health pharmacy database, and multiple data sources for documenting heart rhythm changes during follow-up.
Our study also had limitations. Medication use was not randomly assigned. Our efforts to address healthy user bias and confounding by indication may have been inadequate. Prescription medication use may have been misclassified because participants do not necessarily use prescriptions they fill. We investigated a few classes of cardiovascular medication but left other classes such as diuretics and dihydropyridine CCBs unexplored. Long-standing persistent AF status may have been misclassified by our definition. When we modified the definition to reduce false positives, we were left with insufficient precision to assess the associations of interest. Finally, our cohort included only participants with incident AF who came to medical attention and were diagnosed with a 12-lead ECG; people with undiagnosed AF could not be identified for inclusion.
Our investigation of use of statins and antihypertensive medications among participants whose initial AF episode terminated suggested an association consistent with a protective effect of current statin use. However, noncausal Long-standing persistent atrial fibrillation was defined as atrial fibrillation present on 2 separate occasions 6 to 36 months apart, without any documented sinus rhythm. b Adjusted for age, sex, body mass index, diabetes, hypertension, coronary heart disease, valvular heart disease, heart failure, prior stroke, chronic kidney disease, and current use of antiarrhythmic medication. Models for statins were also adjusted for total cholesterol to HDL ratio. Models for ACE inhibitors or ARBs and for β-blockers were also adjusted for systolic and diastolic blood pressure. The definition of long-standing persistent AF used in primary analyses (see Table 2 ) was AF present on 2 separate occasions 6 to 36 months apart, without any documented sinus rhythm. b Adjusted for age, sex, body mass index, diabetes, hypertension, coronary heart disease, valvular heart disease, heart failure, prior stroke, chronic kidney disease, and current use of antiarrhythmic medication. Models for statins were also adjusted for total cholesterol to HDL ratio. Models for ACE inhibitors or ARBs and for β-blockers were also adjusted for systolic and diastolic blood pressure. c Never, current, and former medication use as of the previous day of follow-up. d To reduce healthy user bias, statin use and ACE inhibitor or ARB use were lagged by 1 year. e To reduce confounding by indication, current β-blocker use was compared with current nondihydropyridine CCB use. Person-time with concurrent use of both a β-blocker and a nondihydropyridine CCB and person-time with no current use of either a β-blocker or a nondihydropyridine CCB were excluded. 
